A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes (Q37253436)

From Wikidata

Jump to navigation Jump to search

scientific article published on 04 October 2012

Language	Label	Description	Also known as
English	A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes	scientific article published on 04 October 2012

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes (English)

1 reference

Europe PubMed Central

19 August 2017

1 reference

based on heuristic

inferred from title

0 references

Human herpesvirus 2

1 reference

based on heuristic

inferred from title

author name string

Ronald L Veselenak

1

1 reference

Europe PubMed Central

19 August 2017

Mark Shlapobersky

2

1 reference

Europe PubMed Central

19 August 2017

Richard B Pyles

3

1 reference

Europe PubMed Central

19 August 2017

Qun Wei

4

1 reference

Europe PubMed Central

19 August 2017

Sean M Sullivan

5

1 reference

Europe PubMed Central

19 August 2017

Nigel Bourne

6

1 reference

Europe PubMed Central

19 August 2017

language of work or name

0 references

publication date

4 October 2012

1 reference

Europe PubMed Central

19 August 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

19 August 2017

30

1 reference

Europe PubMed Central

19 August 2017

7046-7051

1 reference

Europe PubMed Central

19 August 2017

49

1 reference

Europe PubMed Central

19 August 2017

Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Efficacy results of a trial of a herpes simplex vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Vaxfectin: a versatile adjuvant for plasmid DNA- and protein-based vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Herpes simplex virus requires VP11/12 to induce phosphorylation of the activation loop tyrosine (Y394) of the Src family kinase Lck in T lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Herpes Simplex: Insights on Pathogenesis and Possible Vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Herpes simplex virus type 2 transmission: risk factors and virus shedding

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

The potential epidemiological impact of a genital herpes vaccine for women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Once-daily valacyclovir to reduce the risk of transmission of genital herpes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

The Holy Grail: immune control of human herpes simplex virus infection and disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Herpes simplex virus infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Genes that induce immunity--DNA vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Genital herpes infection: a review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

6 September 2017

Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

26 June 2018

Genital reinfection after recovery from initial genital infection with herpes simplex virus type 2 in guinea pigs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

26 June 2018

Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

26 June 2018

Preinfection prophylaxis with herpes simplex virus glycoprotein immunogens: factors influencing efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

26 June 2018

Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

3 September 2018

Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

3 September 2018

Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

3 September 2018

Plasmid DNA-expressed secreted and nonsecreted forms of herpes simplex virus glycoprotein D2 induce different types of immune responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

3 September 2018

Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

3 September 2018

DNA immunization against experimental genital herpes simplex virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

3 September 2018

The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

3 September 2018

Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3807597

3 September 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.057

7 January 2021

Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.057

7 January 2021

Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.09.057

7 January 2021

Identifiers

10.1016/J.VACCINE.2012.09.057

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37253436&oldid=1775326816"